Pancreatic Beta-cell Protection Hot Targets & Pipeline Analysis gives
comprehensive insight on the various drugs being developed for the
treatment of Pancreatic Beta-cell protection. The report covers hot
targets & molecules in research for beta-cell protection in both Type-1
diabetes & Type-2 diabetes disease progression.

This report enables Pharmaceutical /Biotech companies, Academic
institutes, Individual researchers, Investors, Medical technology
companies, Service providers and other associated stake holders to
identify and analyze the available licensing/collaborative commercial
opportunities in the Diabetes Drug market. The report also provides
strategic insights on medicines that are likely to have an impact on
beta-cell protection treatment space and potentially alter standards of
care in the foreseeable future.

Therapies that are presently available for diabetes focus on reducing
the disease symptoms, but there is a huge unmet need for therapies that
can either slow or prevent the beta cell loss as there is a rapid loss
of cells in type 1 diabetes and progressive loss in type 2 diabetes
patients